CDKN1A and cancer: In this study, we revealed for the first time that p21 is a novel synthetic lethal candidate of oncogene KRAS. Overexpression of p21 by cDNA or drugs selectively killed KRAS-mutant cells (Fig. 6), suggesting that p21 is a potential target for the treatment of KRAS-mutant cancer.